Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Mar 6;318(7184):633-8.
doi: 10.1136/bmj.318.7184.633.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

M Rösler  1 , R Anand, A Cicin-Sain, S Gauthier, Y Agid, P Dal-Bianco, H B Stähelin, R Hartman, M Gharabawi
Affiliations
Clinical Trial

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

M Rösler et al. BMJ. .

Erratum in

  • BMJ 2001 Jun 16;322(7300):1456

Abstract

Objectives: To assess the effects of rivastigmine on the core domains of Alzheimer's disease.

Design: Prospective, randomised, multicentre, double blind, placebo controlled, parallel group trial. Patients received either placebo, 1-4 mg/day (lower dose) rivastigmine, or 6-12 mg/day (higher dose) rivastigmine. Doses were increased in one of two fixed dose ranges (1-4 mg/day or 6-12 mg/day) over the first 12 weeks with a subsequent assessment period of 14 weeks.

Setting: 45 centres in Europe and North America.

Participants: 725 patients with mild to moderately severe probable Alzheimer's disease diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, and the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association.

Outcome measures: Cognitive subscale of the Alzheimer's disease assessment scale, rating on the clinician interview based impression of change incorporating caregiver information scale, and the progressive deterioration scale.

Results: At the end of the study cognitive function had deteriorated among those in the placebo group. Scores on the Alzheimer's disease assessment scale improved in patients in the higher dose group when compared with patients taking placebo (P<0.05). Significantly more patients in the higher dose group had improved by 4 points or more than had improved in the placebo group (24% (57/242) v 16% (39/238)). Global function as rated by the clinician interview scale had significantly improved among those in the higher dose group compared with those taking placebo (P<0.001), and significantly more patients in the higher dose group showed improvement than did in the placebo group (37% (80/219) v 20% (46/230)). Mean scores on the progressive deterioration scale improved from baseline in patients in the higher dose group but fell in the placebo group. Adverse events were predominantly gastrointestinal, of mild to moderate severity, transient, and occurred mainly during escalation of the dose. 23% (55/242) of those in the higher dose group, 7% (18/242) of those in the lower dose group, and 7% (16/239) of those in the placebo group discontinued treatment because of adverse events.

Conclusions: Rivastigmine is well tolerated and effective. It improves cognition, participation in activities of daily living, and global evaluation ratings in patients with mild to moderately severe Alzheimer's disease. This is the first treatment to show compelling evidence of efficacy in a predominantly European population.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Outcome of allocation to treatment and reasons for withdrawal from the study
Figure 2
Figure 2
Mean change in baseline scores on cognitive subscale of Alzheimer’s disease assessment scale, observed cases analysis. P<0.05 compared with placebo (two tailed pairwise Student’s t tests using pooled error term from analysis of covariance and analysis of variance
Figure 3
Figure 3
Mean change in baseline scores on the progressive deterioration scale, analysis of last observation carried forward. P<0.05 compared with placebo (two tailed pairwise Student’s t tests using pooled error term from analysis of covariance and analysis of variance
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA. 1994;271:985–991. - PubMed
    1. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med. 1992;327:1253–1259. - PubMed
    1. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer’s disease. JAMA. 1992;268:2523–2529. - PubMed
    1. Roger SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo controlled trial of donepezil in patients with Alzheimer’s disease. Neurology. 1998;50:136–145. - PubMed
    1. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293–303. - PubMed